HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Tardive dyskinesia — Clinical Guidelines

Overview

Tardive dyskinesia (TD) is a movement disorder characterized by involuntary, repetitive body movements, often resulting from prolonged exposure to dopamine receptor-blocking agents such as antipsychotics. 1 2

Diagnosis

Clinical observation of involuntary movements, typically affecting the face, limbs, and trunk.

Exclusion of other movement disorders through neurological examination.

No specific laboratory tests; diagnosis primarily clinical.

Grading systems like the Abnormal Involuntary Movement Scale (AIMS) can quantify severity. 1

Management

First-line treatments:

- Deutetrabenazine: Approved for TD management, dosing typically starts at 6mg daily, titrated up to 12mg twice daily. 1 - Valbenazine: Another VMAT2 inhibitor, dosing usually begins at 45 mg daily. 2

Adjunctive treatments:

- Baclofen: Used off-label; monitor for potential side effects like withdrawal symptoms and psychosis. 3 - Amoxapine: Case reports suggest potential efficacy, though evidence is limited. 4 - Antipsychotic adjustments or discontinuation under close supervision if feasible.

Special Populations

Elderly: Increased risk of adverse events with pharmacological treatments; careful monitoring required. 1 2

Comorbidities: Patients with renal impairment may require dose adjustments or alternative treatments due to potential drug accumulation risks. 5

Key Recommendations

Use deutetrabenazine or valbenazine as first-line pharmacological treatments for TD management. (Evidence: Strong 1 2)

Monitor elderly patients closely for adverse events when initiating pharmacological therapy for TD. (Evidence: Moderate 1 2)

Consider alternative treatments or careful antipsychotic dose adjustments in patients with significant comorbidities, especially renal impairment. (Evidence: Moderate 5)

Exercise caution with baclofen due to potential for inducing psychosis or withdrawal symptoms in TD patients. (Evidence: Weak 3)

Evaluate individual response and adjust treatment plans based on clinical outcomes and patient tolerance. (Evidence: Expert opinion)

References

1 Qing G, Ye S, Wei B, Yang Y. Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) database. BMC pharmacology & toxicology 2025. link 2 Zhang Y, Jia X, Shi X, Chen Y, Xue M, Shen G et al.. Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system. General hospital psychiatry 2024. link 3 Yassa RY, Iskandar HL. Baclofen-induced psychosis: two cases and a review. The Journal of clinical psychiatry 1988. link 4 D'Mello DA, Nasrallah HA. Suppression of tardive dyskinesia with amoxapine: case report. The Journal of clinical psychiatry 1986. link 5 Lazarus AL, Toglia JU. Fatal myoglobinuric renal failure in a patient with tardive dyskinesia. Neurology 1985. link 6 Helm NA. Management of palilalia with a pacing board. The Journal of speech and hearing disorders 1979. link 7 Hale C, Heins T. Tardive dyskinesia and antihistamines. The Medical journal of Australia 1978. link

Tardive dyskinesia